BeiGene
BGNE
#963
Rank
ยฃ15.93 B
Marketcap
ยฃ140.42
Share price
1.02%
Change (1 day)
0.58%
Change (1 year)
BeiGene is a Chinese pharmaceutical company engaged in the R&D, and commercialization of molecularly-targeted, and immuno-oncology drugs for the treatment of cancer.

EPS for BeiGene (BGNE)

EPS in 2023 (TTM): -ยฃ13.93

According to BeiGene 's latest financial reports the company's current EPS (TTM) is -ยฃ13.24. In 2022 the company made an earnings per share (EPS) of -ยฃ15.41 a decrease over its 2021 EPS that were of -ยฃ12.10.

EPS history for BeiGene from 2015 to 2023

Annual EPS

Year EPS Change
2023 (TTM)-ยฃ13.93-9.59%
2022-ยฃ15.4127.35%
2021-ยฃ12.10-19.96%
2020-ยฃ15.1220.81%
2019-ยฃ12.5131.52%
2018-ยฃ9.52417.57%
2017-ยฃ1.84-37.16%
2016-ยฃ2.93158.95%
2015-ยฃ1.13

EPS for similar companies or competitors

Company EPS EPS differencediff. Country
-ยฃ0.80-93.99%๐Ÿ‡บ๐Ÿ‡ธ USA
-ยฃ0.21-98.38%๐Ÿ‡บ๐Ÿ‡ธ USA